PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
The information set forth under this Item 2.02. Results of
Operations and Financial Condition, including the exhibit
attached hereto, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
Attached as Exhibit 99.1 is a copy of a press release of Pieris
Pharmaceuticals, Inc., dated May10, 2017, announcing certain
financial results for the first quarter ended March31, 2017.
| Item9.01 | Financial Statements and Exhibits |
(d)Exhibits.
99.1 Press release announcing financial results for the first
quarter ended March31, 2017, dated May10, 2017.
About PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS)
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate. PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) Recent Trading Information
PIERIS PHARMACEUTICALS, INC. (NASDAQ:PIRS) closed its last trading session up +0.58 at 3.98 with 5,137,885 shares trading hands.
